FKBP51 dysregulation has been documented across a spectrum of neurological disorders—encompassing neurodegenerative pathologies such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, along with cerebrovascular events and gliomas—where it actively participates in disease mechanisms (Chakraborty and Zweckstetter, 2025; Garcia-Gomara et al., 2025; Koren et al., 2011; Liu et al., 2022; Sarkar et al., 2008; Yang et al., 2015). This evidence concerns the gene FKBP4 and glioma.